Investors
Specialized pharmaceutical company for creating market value through experience and innovation
Presentations
Poster presentation of TU2218 at AACR 2024
Poster presentation of TU2218, an oral immune-oncology therapy targeting TGF-beta and VEGF pathways, at the American Association for Cancer Research (AACR) Annual Meeting 2024
